Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4085-4088

  Fujimoto, Akihide ^a   O'Day, Steven J ^b   Taback, Bret ^a   Elashoff, David ^c   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Cancer Institute Medical Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CISPLATIN; DACARBAZINE; DNA; INTERLEUKIN 2; LACTATE DEHYDROGENASE; TAMOXIFEN; VINBLASTINE;

ADULT; ALLELIC IMBALANCE; ARTICLE; BIOCHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER GENETICS; CHROMOSOME 12Q; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC ANALYSIS; HUMAN; MALE; MELANOMA; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SERUM; TREATMENT OUTCOME;

ALLELIC IMBALANCE; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CHROMOSOMES, HUMAN, PAIR 12; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS;

EID: 3042582102     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0957     Document Type: Article

References (20)

1. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (Lond.) 2001;409(6817):207-11.
2. Moroni MC, Hickman ES, Denchi EL, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001;3(6):552-8.
3. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001;61(18):6660-4.
4. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2(4):277-88.
5. Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box: new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 2001;7(5): 191-4.
6. Fujimoto A, Takeuchi H, Taback B, et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004;64(6):2245-50.
7. O'Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17(9): 2752-61.
8. O'Day SJ, Boasberg PD, Piro L, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8(9):2775-81.
9. Atkins MB, Gollob JA, Sosman JA, et al. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002;8(10):3075-81.
10. McDermott DF, Mier JW, Lawrence DP, et al. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000;6(6):2201-8.
11. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16(5):1752-9.
12. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2(9):1035-7.
13. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst (Bethesda) 2002;94(21):1614-9.
14. Chen X, Bonnefoi H, Diebold-Berger S, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999;5(9):2297-303.
15. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60(24):6878-81.
16. Fujiwara Y, Chi DD, Wang H, et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999;59(7):1567-71.
17. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001;61(15):5723-6.
18. Nakayama T, Taback B, Nguyen DH, et al. Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients. Ann NY Acad Sci 2000;906: 87-98.
19. Hoon DS, Bostick P, Kuo C, et al, Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000;60(8):2253-7.
20. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64(1):218-24.